Steven Pieper Biography and Net Worth

CFO of Xeris Biopharma

Steve Pieper is the Chief Financial Oﬃcer of Xeris Pharmaceuticals, having previously served as Vice President of Finance since he joined the company in 2017. Mr Pieper brings over 20 years of experience working in the life science industry in various financial leadership roles.

Prior to Xeris, Mr. Pieper served as the CFO and COO of Catheter Connections Inc., a company focused on the development and commercialization of innovative vascular access products designed to protect patients from acquiring infections during intravenous infusion therapy. Catheter Connections, Inc. was acquired by Merit Medical in January 2016. Mr. Pieper also held the position of Director of Finance at Durata Therapeutics Inc., a biopharmaceutical company, which was acquired by Actavis (now Allergan) in November 2014. Mr. Pieper started his career in healthcare at Baxter Healthcare Corporation, where he held a variety of commercial and corporate decision support ﬁnance roles.

Mr. Pieper received an MBA from Loyola University, Chicago and BS in Finance from DePaul University.

What is Steven Pieper's net worth?: The estimated net worth of Steven Pieper is at least $11.94 million as of July 6th, 2026. Mr. Pieper owns 1,393,653 shares of Xeris Biopharma stock worth more than $11,936,638 as of July 8th. This net worth evaluation does not reflect any other investments that Mr. Pieper may own. Learn More about Steven Pieper's net worth.
How do I contact Steven Pieper?: The corporate mailing address for Mr. Pieper and other Xeris Biopharma executives is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. Xeris Biopharma can also be reached via phone at (844) 445-5704 and via email at [email protected]. Learn More on Steven Pieper's contact information.
Has Steven Pieper been buying or selling shares of Xeris Biopharma?: During the last ninety days, Steven Pieper has sold $383,052.00 in Xeris Biopharma stock. Most recently, Steven Pieper sold 27,600 shares of the business's stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $8.52, for a transaction totalling $235,152.00. Following the completion of the sale, the insider now directly owns 1,366,053 shares of the company's stock, valued at $11,638,771.56. Learn More on Steven Pieper's trading history.
Who are Xeris Biopharma's active insiders?: Xeris Biopharma's insider roster includes Barbara-Jean Bormann-Kennedy (Director), James Brady (Director), Paul Edick (Insider), Dawn Halkuff (Director), Beth Hecht (Insider), John Johnson (Director), Kevin McCulloch (President and Chief Operating Officer), Marla Persky (Director), Steven Pieper (CFO), John Shannon, Jr. (Insider), and Jeffrey Sherman (Director). Learn More on Xeris Biopharma's active insiders.
Are insiders buying or selling shares of Xeris Biopharma?: In the last year, insiders at the sold shares 26 times. They sold a total of 783,617 shares worth more than $5,702,760.60. The most recent insider tranaction occured on July, 7th when insider Steven Pieper sold 27,600 shares worth more than $235,152.00. Insiders at Xeris Biopharma own 4.4% of the company. Learn More about insider trades at Xeris Biopharma.
Information on this page was last updated on 7/7/2026.

Steven Pieper Insider Trading History at Xeris Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/7/2026	Sell	27,600	$8.52	$235,152.00	1,366,053
7/6/2026	Sell	17,400	$8.50	$147,900.00	1,393,653

Steven Pieper Buying and Selling Activity at Xeris Biopharma

Xeris Biopharma Company Overview

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Today's Range

Now: $8.63

$8.48

$8.92

50 Day Range

MA: $6.71

$5.89

$8.94

2 Week Range

Now: $8.63

$4.82

$10.08

Volume

2,065,230 shs

Average Volume

1,915,337 shs

Market Capitalization

$1.49 billion

P/E Ratio

143.92

Dividend Yield

N/A

Beta

0.62